Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Goldmans Sachs
CRO
Parexel snapped up, again, as Goldman Sachs, EQT spend $8.5B
Parexel is being bought out for $8.5 billion.
Ben Adams
Jul 2, 2021 11:33am
4G Clinical gets $230M from Goldman Sachs to expand RTSM reach
Jun 29, 2021 8:00am
Bannister joins SVB to help companies raise cash
Apr 8, 2021 8:40am
Synthetic biology manufacturer Zymergen raises another $400M
Dec 14, 2018 4:29pm
Telehealth firm 98point6 nets $50M in round led by Goldman Sachs
Oct 30, 2018 9:00am
Outcome Health valued at $5.5B with first financing round of $500M
May 31, 2017 5:27pm
